Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Chris Labaki(Beth Israel Deaconess Medical Center), Toni K. Choueiri(Harvard University), Ziad Bakouny(Dana-Farber Cancer Institute), J. Connor Wells(Queen's University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Sumanta K. Pal(City of Hope), Matthew Scott Ernst(University of Calgary), Bernadett Szabados(Queen Mary University of London), Rana R. McKay(University of California San Diego), Georg A. Bjarnason(Sunnybrook Health Science Centre), Bradley A. McGregor(Harvard University), Wenxin Xu(Dana-Farber Cancer Institute), Jae‐Lyun Lee(Ulsan College), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Francis Parnis, Takeshi Yuasa(Japanese Foundation For Cancer Research), Daniel Yick Chin Heng(University of Calgary), Audreylie Lemelin(University of Calgary)
Cited by 4
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k